Wen-Feng Gong
Overview
Explore the profile of Wen-Feng Gong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Qi L, Ma L, Chen Y, Chen Z, Zhong J, Gong W, et al.
Ann Med
. 2019 Dec;
52(1-2):21-31.
PMID: 31876201
Hepatic resection is the first-line treatment for hepatocellular carcinoma (HCC). Whether to perform anatomical (AR) or non-anatomical resection (NAR) remains controversial. This retrospective study compares the outcomes according to the...
12.
Gong W, Zhong J, Lu Z, Zhang Q, Zhang Z, Chen C, et al.
Biosci Rep
. 2019 Aug;
39(8).
PMID: 31383787
To explore clinical factors associated with extent of liver regeneration after hemihepatectomy to treat hepatocellular carcinoma (HCC). Future liver remnant volume (as a percentage of functional liver volume, %FLRV) and...
13.
Yue H, Wang M, Gong W, Zhang L
FEMS Microbiol Lett
. 2018 Oct;
365(22).
PMID: 30289449
Bipolaris sorokiniana is a soil-borne fungal pathogen causing common root rot in wheat, and is difficult to control through chemical and agricultural means. Chaetomium spp. have been documented as potential...
14.
Qi L, Xiang B, Wu F, Ye J, Zhong J, Wang Y, et al.
Cancer Res
. 2018 Jun;
78(16):4731-4744.
PMID: 29915159
To clarify the significance of circulating tumor cells (CTC) undergoing epithelial-mesenchymal transition (EMT) in patients with hepatocellular carcinoma (HCC), we used an advanced CanPatrol CTC-enrichment technique and hybridization to enrich...
15.
Zhong J, Peng N, You X, Ma L, Xiang X, Wang Y, et al.
Oncotarget
. 2017 Apr;
8(11):18296-18302.
PMID: 28407686
The current clinical reality of tumor stages and primary treatments of hepatocellular carcinoma (HCC) is poorly understood. This study reviewed the distribution of tumor stages and primary treatment modalities among...
16.
Zhong J, Pan L, Wang Y, Cucchetti A, Yang T, You X, et al.
Medicine (Baltimore)
. 2017 Apr;
96(15):e6608.
PMID: 28403105
This study aims to refine the designation for single hepatocellular carcinoma (HCC) >5 cm by comparing the postresection prognosis of these patients with those who have a single-tumor ≤5 cm...
17.
Gong W, Zhong J, Lu S, Wang X, Zhang Q, Ma L, et al.
Oncotarget
. 2017 Jan;
8(9):15047-15056.
PMID: 28122361
The ability of antiviral therapy to reduce risk of post-hepatectomy hepatitis B virus (HBV) reactivation in patients negative for viral DNA is unclear. This prospective study involved 174 consecutive patients...
18.
Zhong J, Ke Y, Zhu S, Wang L, Luo C, Gong W, et al.
Onco Targets Ther
. 2016 Nov;
9:6897-6907.
PMID: 27877054
Aim: Lamivudine (LAM) and adefovir dipivoxil (ADV) are widely used in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but few studies have directly compared their therapeutic efficacy and...
19.
Tan J, Zhao C, Peng N, Yang Y, Zhong J, Yang T, et al.
J Surg Oncol
. 2016 Sep;
114(8):966-970.
PMID: 27633143
Aim: The suitability of hepatic resection for older patients remains controversial. This study aimed to investigate whether age influences overall survival of patients with hepatocellular carcinoma (HCC) after resection. Methods:...
20.
Gong W, Zhong J, Xiang B, Li L
Mol Clin Oncol
. 2016 Jun;
5(1):3-6.
PMID: 27330754
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortalities, and its prevalence is expected to increase in future decades. Hepatitis B virus (HBV) infection is the leading cause...